UIC-2012-013 – Pharmaceutical Compositions for Sleep Disorders

UIC researchers propose pharmacologic compositions with demonstrated efficacy in two human pilot studies. Exemplary embodiments consist of a combination regimen of ondansetron (24 mg/day) and fluoxetine (10 mg/day). Both clinical studies evidence a significant improvement of patient apnea–hypopnea index (AHI) over baseline severity. Neither studies observed a significant difference in adverse events from drug treatment. Moreover, this combination was also paired with a Mandibular Advancement Device (MAD) in the 2017 clinical study to good effect. The golden-standard for OSA treatment is airway pressure devices such as the CPAP. However, the success of airway pressure devices is highly dependent on adherence, which is historically low. Other treatments include lifestyle changes, oral appliances, and surgery. The sleep apnea devices market, which dominates the OSA treatment market, will reach 6 billion USD in 2019 with a CAGR of 7.8%. Nelson Grihalde grihalde@otm.uic.edu 312-996-4129